According to Genzyme, Synvisc-One is the only single-injection viscosupplement approved for the treatment of osteoarthritis knee pain in the US. It is also approved in the EU and a number of Asian and Latin American countries. Genzyme will begin making Synvisc-One available immediately.
Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme, said: “Synvisc-One is an important therapy for osteoarthritis of the knee because it delivers long-term pain relief through a single injection without the systemic side effects that can be caused by steroids and anti-inflammatory medication. We expect that the approval of Synvisc-One will be a significant growth driver for the Synvisc franchise.”